Skip to content
Chemoprotection
Radioprotection
Anti-Cancer Research
Discovery Research
Additional Resources

2022 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

ALRN-6924 Induces Cell Cycle Arrest in Bone Marrow Stem Cells and Hair Follicles with DoseDependent Degree and Duration of Effects after a Single Infusion in Healthy Volunteers

View Poster

2022 European Society for Dermatological Research Annual Meeting

Temporary Cell Cycle Arrest in Human Scalp Hair Follicles and Their Epithelial Stem Cells by ALRN-6924: A Novel Strategy to Selectively Protect p53-Wildtype Cells Against Paclitaxel and 4-HC-Induced Alopecia

View Presentation

2022 Society for Investigative Dermatology Annual Meeting

Temporary Cell Cycle Arrest by ALRN-6924 Selectively Protects Human Scalp Hair Follicles and Their Epithelial Stem Cells from Taxane-Induced Toxicity

View Presentation

2021 European Society Of Medical Oncology (ESMO) Virtual Congress

A Phase 1b Study of the Dual MDMX/MDM2 Inhibitor, ALRN-6924, for the Prevention of Chemotherapy-induced Myelosuppression

View Poster

A Phase 1 Study of the Dual MDMX/MDM2 Inhibitor, ALRN 6924, in Healthy Volunteers

View Poster

2021 International Society For Experimental Hematology (ISEH) 50th Annual Scientific Meeting

ALRN-6924 is a Dual MDMX/MDM2 Inhibitor and Can Protect the Bone Marrow of Cancer Patients Treated with Chemotherapy

View Poster

2020 EORTC-NCI-AACR Symposium On Molecular Targets And Cancer Therapeutics

Prevention of Chemotherapy-induced Myelosuppression in SCLC Patients Treated with the Dual MDMX/MDM2 Inhibitor ALRN-6924

View Poster

2019 AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics

The Investigational Peptide Drug ALRN-6924, a Dual Inhibitor of MDMX and MDM2, is an Effective Myelopreservation Agent

View Poster

Interested in partnering with Aileron?
Please contact us.